Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (January 2020)
39 slides from Adma Biologics's investor presentation, Jan 13, 2020
Slide 1: ADMA Biologics
ADMA Biologics REALIZING THE POTENTIAL OF PLASMA-DERIVED THERAPIES WITH GROUNDBREAKING IMMUNOTECHNOLOGY January 2020 NASDAQ: ADMA
Slide 2: Forward-Looking Statements
Forward-Looking Statements GREY ‘This presentation contains “Yorwardockng statements," pursuanttothesafe harbor provisions of the PrivateSecurties Ligation Reform ct of 1985, bout ADMABiolagics, Inc ("we,"*our" or the Company’) including, withoutlimitation,statementsthat may predict, forecast indica
Slide 3: ADMA Biologics is an end-to-end commercial biopharmaceutical company
ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection We believe our devoti
Slide 4: What We Do
What We Do PLASMA COLLECTION ‘ADMA BioCenters (FDALlicensed operation) & Long-term supply contracts in place MANUFACTURING TESTING 3 ae Plasma-Derived Biologics VALIDATION Production Facility ecocasi ee & MEDICAL AFFAIRS 2 Strategy and immunoglobulins ON-SITE: a QC Testing Laboratory i: SS en, Cold-
Slide 5: ADMA Investment Highlights
ADMA Investment Highlights Gate Operating in the plasma-derived therapeutics industry, a unique area of healthcare that has a track record of long- term growth and durability US Market Size 2018 Forecasted to Grow to IG=$6.8B , 7 ~$13.9B | CAGR 10.9% jf venctreeme AMG py 2025 2020-2025 ef Very few p
Slide 6: ADMA Investment Highlights
ADMA Investment Highlights High Barriers to En Manufacturing & Reg Significant CAPEX required to bi fractionation fa with Iong timelines To market plasma products for the US, products must be made from US donor plasma in FDA-approved biologics manufacturing plants Regulatory Barriers - Strict rules
Slide 7: ADMA Offers a Multi-Faceted Revenue-Generation Platform
LADMA @ ADMA Offers a Multi-Faceted Revenue-Generation Platform VEN Contract manufacturing and laboratory services Source Plasma Supply 2$250M Annual Revenue Potential ADMA BioCenters provides source plasma to 3rd parties |G production and processi ee ; e Plasma protein intermediate paste sales to 3
Slide 8: Introduction to Plasma-Derived Therapies and Production
Introduction to Plasma-Derived Therapies and Production GSEEY Plasma-derived therapeutics are essential, Immunoglobulins (IG) or Intravenous Immune Globulin je-sustaining biologic drugs which replace absent (IVIG) isa pooled plasma-derived product from healthy plasma proteins due to genetic and acqu
Slide 9: Overview: Production of Plasma-Derived Therapies
LADMA @ Overview: Production of Plasma-Derived Therapies COHN-ONCLEY COLD ETHANOL FRACTIONATION PROCESS Raw Material Manufacturing Collections Release Testing Fractionation Purification (upstream) (downstream) Plasmapheresis ‘Source Plasma for — } Fraction | ESS) Approximately 4-6 months. Includes a
Slide 10: Plasma Collection Centers: ADMA BioCenters
Plasma Collection Centers: ADMA’ >
Slide 11: Plasma Centers are Essential to Ensure Raw Material Supply
Plasma Centers are Essential to Ensure Raw Material Supply to Produce IG and Other Plasma Proteins Expertise since 2014 — First ADMA BioCenter FDA-approved + Dedicated business unit with specialized staff and management oversight + Compliant with FDA and PPTA requirements Each center uses the latest
Slide 12: Expanding the ADMA BioCenter Network - 2020 Forward
Expanding the ADMA BioCenter Network - 2020 Forward pproved valida’ documentation in place Opening additional Plan to build between Realize forecasted economies of scale as collections centers — low regulatoryrisk | 5 to 10 new collection increase reducing the overall cost per L and rapid time tofir
Slide 13: Plasma Product Manufacturing Overview
|APMA _) Plasma Product Manufacturing Overview
Slide 14: ADMA: One of a Few Manufacturers of Specialty Immune Globulins in the US
ADMA: One of a Few Manufacturers of Specialty Immune Globulins in the US LAMA @ Acquired the Boca Raton, FL facility June 2017 FDA product approvals and new license granted in 2019 FDA-approved products include: BIVIGAME (immune globulin intravenous, human) ASCENIV™ (immune globulin intravenous — si
Slide 15: Leveraging Our Vertical Integration with End-to-End Control
Leveraging Our Vertical Integration with End-to-End Control ADMA BioCenters & Long-term supply contracts In-house specialty teamto oversee 3rd party operations Fractionation & purification Rawmaterials In process production 3rd Party collectors provide ein inte e Final release tate i pencemars Plasm
Slide 16: ADMA's Plant - How Much Product Could Be Produced Annually?
ADMA’s Plant — How Much Product Could Be Produced Annually? 400,000 L world-class plasma fractionation and purification plant + Located in: Boca Raton, FL | Total Staff: ~350 Total maximum production potential today: 400,000L x 3.5-4g per L = 1.4M to 4.6M grams of finished IG + Potential for >$250M
Slide 17: ADMA Is Well Positioned for Near and Long-Term Growth
ADMA Is Well Positioned for Near and Long-Term Growth with Gate Reasonable Investments in CAPEX SCALE PLASMA COLLECTION CENTER NETWORK WITH FORECASTED IG PRODUCTION RAMP Ramp plasma collection center build-out with forecasted plant processing throughputin a controlled and complaint manner Anticipate
Slide 18: Commercial Opportunity: Plasma Products Portfolio
ARMA COMMERCIAL OPPORTUNITY: PLASMA PRODUCTS PORTFOLIO BIVIGAM _ Nabi TMMUNE GLOBULIN INTRAVENOUS HepatsB (ROMAN, 10; uid ‘nme Gui sen)
Slide 19: Plasma IG Market Is Sizeable & Growing
es I eee eee Plasma IG Market Is Sizeable & Growing IMMUNE GLOBULIN (IG or IVIG) is a pooled plasma product ~$6.8 Billion U.S. Immune Globulin (IG) Market* from healthy plasma donors, containing a range of polyclonal U.5.1G market (2010-18) antibodies against common pathogens Forecast 2019-2025 $15.
Slide 20: IG is Widely Used and Reimbursed Across Payer Mix
es I eee eee IG is Widely Used and Reimbursed Across Payer Mix LADMA @ FDA-Approved Uses* Possible Additional Reimbursed Evidence-Based Uses Primary immunodeficiency (PI) Acquired red cell aplasia Multiple myeloma Rasmussen's syndrome Multifocal motor neuropathy Bone marrow transplantation Myastheni
Slide 21: Primary Immunodeficiency is a Significant Market Opportunity
Primary Immunodeficiency is a Significant Market Opportunity Primary Immunodeficiency: Epidemiology overview Over 350 genetic disorders are classified within PI — ~250,000 PI PATIENTS in the U.S. — ~50% are treated with IG The ADMA portfolio of Ig Products offers alternatives and can help treat majo
Slide 22: Commercial Products: BIVIGAM
es I eee eee Commercial Products: JADMIA @ BIVIGAM IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID BIVIGAM® (Immune Globulin Intravenous, Human) FDA-APPROVED PROTECTION AGAINST SERIOUS INFECTIONS +Indicated for the treatment of Patients with PI *Contains a wide spectrum of polyclonal antibodies agai
Slide 23: Commercial Products: ASCENIV
Commercial Products: ASCENV OBULIN IR UI ASCENIV™ (immune Globulin Intravenous - sir, Human) FDA-APPROVED PROTECTION AGAINST SERIOUS INFECTIONS + Indicatedtor the treatment of patients with PI *Contains awide spectrum of polyclonal antibodies against endemic pathogens Manufactured through ADMA’s pat
Slide 24: Commercial Products: Nabi-HB
Commercial Products: JADMIA @ Hepatitis 8 immune Globulin (Human) NABLHB® (Hepatitis B Immune Globulin, Human) FDA-APPROVED TO PROVIDE ENHANCED IMMUNITY AGAINST HEPATITIS B Successfully used for over 20 years to protect against Hepatitis 6 infection among newly exposed individuals -Manufactured from
Slide 25: Commercialization/Distribution Strategy for ADMA's Immunoglobulins
Commercialization/Distribution Strategy for ADMA’s Immunoglobulins LAMA @ Distribution channel is well defined roy HOSPITAL Inpatients — hospital based ‘HOME CARE COMPANIES PHARMACY Well established distribution organizations ty ” cry products efficenty BioCare SD Sy) a rangers AmerisourceBergen buy
Slide 26: US Plasma Products Competitive Landscape
US Plasma Products Competitive Landscape LAMA @ Presently, the US IG marketis led by 4 major producers + CSL Behring, Grifols, Takeda (Shire), Octapharma account for approximately 90% of US market 2018 US IG Market Share 7% 3% Market is growing between ~6-11% annually a Growth has historically been
Slide 27: Creating & Unlocking Value: Intellectual Property and R&D Pipeline
ARMA Creating & Unlocking Value: INTELLECTUAL PROPERTY AND R&D PIPELINE
Slide 28: Despite Decades of IG Use, Patients Continue to Advocate for Improved Therapies
Despite Decades of IG Use, Patients and Treaters Continue to Advocate for Improved Therapies and Treatment Options Despite standard immune globulin therapy, patients continue to experience recurrent respiratory infection and chronic lung disease’? >90” of PI patients on standard IVIG experience recu
Slide 29: ADMA's Patented Immunotechnology is Used to Manufacture ASCENIV
ADMA’s Patented Immunotechnology is Used to Manufacture ASCENIV™ PATENTS ISSUED 9,107,906 - Composition 9,714,283 -Use 9,815,808 - Methods Expiration 2035 ‘These patents includethe tse of G for treatment and Preventionofall viral Induced respiratory infections Discover ADMA Biologics Patented Immuno
Slide 30: ADMA Biologics Pipeline
ADMA Biologics Pipeline LADMA @ nal target populations for ASCENIV™ As previously disclosed, we believe the published data and FDA approval of ASCENIV™ better positions ADMA to further its mission to evaluate ASCENIV™ in immune-compromised patients infected with or at-risk for Respiratory Syncytial
Slide 31: ADMA Biologics Pipeline
ADMA Biologics Pipeline Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumoniainfection + The patent (expiration date 2037) claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling t
Slide 32: Our R&D Commitment: S. pneumonia
ADMA ) BIOLOGICS Our R&D Commitment: S. pneumonia: ADMA’s patent and . Significant ps at a donor stimulation Doing Better problematic — Lesa oh Se methods work to For Donors pathogen evenin E improve healthcare . this age of vaccine nee for donors and Doing Better preventable be patients at risk for
Slide 33: S. pneumonia: A Leading Cause of Illness and Death
S. pneumonia: A Leading Cause of Illness and Death Is estimated to cause about 900,000 pneumococcal pneumonia infections within the United States per year, resulting in 450,000 hospitalizations” Is the most common cause of community acquired pneumonia (CAP) in 900,000 cases the United States! annual
Slide 34: Milestones, Corporate and Financial Highlights
ARMA Milestones, Corporate and Financial Highlights
Slide 35: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors LADMA @ Psame | SELECTEDCURRENToRPASTAFFUATIONS ‘Adam Grossman Founder, President, nal S G Pasa — _ ee nn ErecutwevicPreicentChiet sh Sues eo = © aan AISING = teuemacusr BED Boies = GC DES mame = STUN Aner an : KEDRION Dredor FR PharmAthene li Fiise
Slide 36: Financials
Financials JADMA @) N wine Montns | Months Current Financial Overview 2019 Financial 2018 4018 FY 2019 FY2018 Results Financial Results Revenues $17.3M $12.9M $11.9M* | $4.1M | $29.2M* $17.0M Total Operating Expenses $50.9M $56.7M | Loss per common share $(0.72) $(1.06) | Cash and cash equivalents $
Slide 37: Upcoming Milestones
Upcoming Milestones OBJECTIVES heer launchand first sales of ASCENIV™ MY cxecute supply agreementto produce and sell intermediate fractions Q Continue production ramp for first full year of commercial sales across IG product portfolio Q Expand plasma collection facility network Q Evaluate and implem
Slide 38: Investment and Corporate Highlights
Investment and Corporate Highlights 3 FDA-approved commercial IG products with total IG manufacturing process revenue potential of ~$250M annually FDA compliant production facility with 400,000L processing capacity with potential for expansion End-to-end control of supply chain offers opportunities
Slide 39: Thank You
ARMA Thank You
ADMA Biologics — Investor Presentation (January 2020) on 6ix